About Citeline

FEATURED CONTENT

• Zeroing In On The Right Patients With RWD & Proprietary Data

  Complex I/E criteria? Seeking broad demographic representation? Don’t know where to find eligible patients? No problem! See how comprehensive data and a connected ecosystem combine to revamp recruitment.

• The Future Of Patient Recruitment: Leveraging RWD For Precision

  To combat the costly challenges of patient recruitment and keep trials on track, sponsors can leverage real-world data.

• Unlocking The Potential of RWD In Clinical Trial Recruitment

  Explore how real-world data (RWD) is transforming recruitment strategies and leveraging technologies such as AI and machine learning.

• Overcoming Complex Patient Recruitment Challenges With Data

  Overcome roadblocks to recruiting patients for rare disease clinical trials with RWD and RWE, including lack of diagnosis and stringent I/E criteria, geographic dispersion, and high dropout rates.

• Global Trial Disclosure Landscape Grows Increasingly Complex

  The industry is witnessing a global trend toward increased transparency and more stringent enforcement of clinical trial reporting requirements. However mechanisms and penalties differ significantly across regions and countries.

• Faster Trial Planning and Site Selection

  Address the challenges of identifying the most suitable trial sites and investigators while optimizing feasibility planning, reducing screen failure rates, and improving patient retention.

• A Dip In NAS Launches Annual Review 2025 Supplement

  Even though new active substance (NAS) launches declined 11% in 2024, this still represented the fourth-highest total of newcomers to the pharma runway recorded and predictions remain good for 2025.

• Life Sciences Companies Talk Past, Present, And Future At JPM

  The 43rd annual J.P. Morgan Healthcare Conference featured presentations from a host of large, medium, and small-cap life sciences companies that discussed past performance and future outlooks.

• Continued Growth In Pharma R&D For 2025

  Explore this breakdown of the key findings in Citeline's full Pharma R&D Annual Review 2025 through easy-to-understand graphs and charts that highlight trends in the R&D pipeline.

• Rare Disease R&D: Continued Growth Amid Challenges

  The market for rare disease treatments continues to grow but it is not without its challenges, including small patient populations and a lack of existing research.

• Outlook 2025: Key Trends & Insights

  Dive into the key trends and challenges shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies.

• Answer Your Critical Clinical Questions — Faster Than Ever

  Pressing clinical planning questions to ask about feasibility, investigator selection, patient enrollment, clinical trial disclosure, and more.

• Antibody-Drug Conjugates: 'Magic Bullets' Become Reality

  Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including antibody-drug conjugates (ADCs). Learn more about ADCs’ makeup, mechanisms, and the development landscape.

• The Scoop On The SCOPE Summit

  From industry partnerships to patient recruitment to proprietary data, SCOPE 2025 was packed with informational sessions.

• Merits Of A Multifaceted Approach To Clinical Trial Recruitment

  The best way to address clinical trial recruitment challenges is with a multifaceted approach that goes beyond traditional channels and ways of thinking.

• Use Case: A Patient-Centric Approach To Site Selection

  Discover how Citeline’s robust datasets, combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease. 

• What's The Current & Future Impact Of AI On Pharmaceutical R&D

  Explore the results of a survey where senior decision-makers in the life sciences industry provided their perceptions and expectations of AI to understand current AI adoption trends.

• What Does 2025 Hold For Pharma?

  Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

• Top 10 Tips For Diversity Plans

  Explore the updated guidance from the FDA to enhance diversity in clinical trials, including ten times to developing a comprehensive Diversity Action Plans.

• Artificial Intelligence Regulation

  To make the best use of artificial intelligence (AI), drug sponsors need to understand where health authorities are drawing the lines.